Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: heltzen (2)

Spartan Capital Annual Investor Conference
heltzeninvestor
CEO of eXoZymes to Present at Spartan Capital Securities’ Second Annual Investor ConferenceOctober 29, 2025
CEO of eXoZymes to Present at ThinkEquity’s Annual Investor Conference
heltzeninvestor
CEO of eXoZymes to Present at ThinkEquity’s Annual Investor ConferenceOctober 23, 2025
Podcast: 'The Catalyst' interviews CEO, Michael Heltzen
heltzenpress clippingsvideopodcast
Podcast: 'The Catalyst' interviews CEO, Michael HeltzenOctober 17, 2025
Inside Biotech podcast interviews CEO, Michael Heltzen
heltzenpress clippingsvideopodcast
Podcast: 'Inside Biotech' interviews CEO, Michael HeltzenOctober 2, 2025
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health Epidemic
heltzeninvestorpress clippingsvideo
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health EpidemicSeptember 18, 2025
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 months
heltzenpress releaseinvestornutraceuticalsvideoscience
eXoZymes biomanufacturing breakthrough: From concept to gram-scale NCT in only 5 monthsJuly 22, 2025
Michael Heltzen & Erum Azeez Khan
heltzenpress releaseinvestorpress clippingsvideopodcast
Podcast: eXoZymes highlights scalable biomanufacturing platform and first spinout, NCTx, on 'Grow Everything'May 16, 2025
Slack Capital: EXOZ investment report and CEO interview
heltzeninvestorpress clippingsvideo
Slack Capital: EXOZ investment report and CEO interviewMay 13, 2025
ARCHIVE: Fox Business: Interview with CEO Michael Heltzen
heltzeninvestorpress clippingsvideoARCHIVE
ARCHIVE: Fox Business: Interview with CEO Michael HeltzenMarch 3, 2025
ARCHIVE: Watch eXoZymes' Nasdaq closing bell ceremony
heltzeninvestorvideoARCHIVE
ARCHIVE: Watch eXoZymes' Nasdaq closing bell ceremonyFebruary 20, 2025
Previous page
Page 2 of 3
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark